Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study
Authors:
Open Access
- 14 August 2017
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 15 (10) , 2017-2028
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Comparison of the effect of the anti‐Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assaysInternational Journal of Laboratory Hematology, 2016
- The laboratory's 2015 perspective on direct oral anticoagulant testingJournal of Thrombosis and Haemostasis, 2016
- Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary PhysicianThe Journal of the American Board of Family Medicine, 2015
- Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherenceEP Europace, 2015
- A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxabanJournal of Thrombosis and Thrombolysis, 2013
- The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?Vascular Pharmacology, 2013
- Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and HaemostasisJournal of Thrombosis and Haemostasis, 2013
- Effect of dosing frequency on chronic cardiovascular disease medication adherenceCurrent Medical Research and Opinion, 2012
- Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillationThrombosis and Haemostasis, 2012
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThrombosis and Haemostasis, 2010